Omid Hamid - Concepedia

Author

Omid Hamid

Angeles Clinic and Research Institute ORCID

Also Known As

Dedee F. Murrell, Hamid, O., O A Hamid, O Hamid, O. Hamid, OMAIMA A HAMID, Omaima A Hamid, Omaima A Hamid MD, Omaima A. Hamid, Omer Eladil Hamid

857

Publications

82.7K

Citations

H-Index

120

Concepts

All Affiliations

Angeles Clinic and Research Institute Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Moffitt Cancer Center

About

Omid Hamid is an author at Angeles Clinic and Research Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	59	189	29.5K
2	Health Sciences	29	58	6.7K
3	Allergy	3	3	59
4	Engineering	1	1	20
5	Biochemistry	1	1	73

Omid Hamid

289

Publications

79.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Nature MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology	2014	5.2K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Jedd D. Wolchok, Axel Hoos, Steven O’Day, Clinical Cancer Research	2009	3.2K
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Journal of Clinical Oncology	2015	2.1K
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert, Antoni Ribas, Jedd D. Wolchok, The Lancet OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanoma	2014	1.7K
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas, Igor Puzanov, Reinhard Dummer, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsImmune Checkpoint Inhibitor	2015	1.5K

Page 1